GlassScriptPhysician profile
Vani Manyam
NPI 1568415859
$5,474.19
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,232 · 2020: $1,183 · 2021: $59.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $484.92 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $465.63 | 2019-2020 | |
| Amgen INC. | $429.26 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $417.05 | 2019-2020 | |
| Genentech USA, INC. | $404.40 | 2019-2020 | |
| Pfizer INC. | $367.10 | 2019-2020 | |
| Lilly USA, LLC | $324.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $321.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $291.62 | 2019-2020 | |
| Eisai INC. | $218.97 | 2019-2020 | |
| Seagen INC. | $186.09 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $157.87 | 2019 | |
| Astellas Pharma US INC | $155.99 | 2020 | |
| Tesaro, INC. | $148.80 | 2019 | |
| Genzyme Corporation | $128.04 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $124.74 | 2019 | |
| Genentech, INC. | $96.36 | 2019 | |
| Abbvie INC. | $86.75 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $74.57 | 2019-2021 | |
| Clovis Oncology, INC. | $67.57 | 2019-2020 | |
| Incyte Corporation | $60.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.53 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.25 | 2019-2020 | |
| Exelixis INC. | $44.50 | 2019 | |
| Array Biopharma INC | $43.73 | 2019 | |
| Acceleron Pharma, INC. | $34.20 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $25.20 | 2019 | |
| Celgene Corporation | $21.91 | 2019 | |
| Taiho Oncology, INC. | $21.63 | 2019 | |
| Dova Pharmaceuticals | $18.09 | 2020 | |
| Eusa Pharma (US) LLC | $16.60 | 2019 | |
| Foundation Medicine, INC. | $16.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.38 | 2019 | |
| Glaxosmithkline, LLC. | $15.58 | 2020 | |
| Beigene USA, INC. | $13.73 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $13.61 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $11.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vani Manyam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.